Reduction of Coagulation Factor XIII Concentration in Patients with Myocardial Infarction, Cerebral infarction, and other Thromboembolic Disorders

Norma Alkjaersig; Anthony P. Fletcher; Martin Lewis; Roy Ittyerah

doi:10.1055/s-0038-1651904

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1977; 38(04): 0863-0873
DOI: 10.1055/s-0038-1651904

Original Article

Schattauer GmbH

Reduction of Coagulation Factor XIII Concentration in Patients with Myocardial Infarction, Cerebral infarction, and other Thromboembolic Disorders

Norma Alkjaersig

¹Washington University School of Medicine, Box 8073, 660 South Euclid Avenue, Department of Medicine, St. Louis, Missouri 63110, U.S.A.

,

Anthony P. Fletcher

¹Washington University School of Medicine, Box 8073, 660 South Euclid Avenue, Department of Medicine, St. Louis, Missouri 63110, U.S.A.

,

Martin Lewis

¹Washington University School of Medicine, Box 8073, 660 South Euclid Avenue, Department of Medicine, St. Louis, Missouri 63110, U.S.A.

,

Roy Ittyerah

¹Washington University School of Medicine, Box 8073, 660 South Euclid Avenue, Department of Medicine, St. Louis, Missouri 63110, U.S.A.

› Author Affiliations

Abstract

Summary

Coagulation factor XIII and plasma fibrinogen chromatographic assays have been performed serially in patients suffering from acute myocardial and cerebral infarction, and in others with disseminated intravascular coagulation. The findings were compared with 2 groups of “controls”; normal clinically-well subjects and hospitalized patients with cerebral infarction who exhibited minimal, stable, or improving neurological deficits. Substantial depression of factor XIII concentrations developed in the 3 patient groups, together with concomitant significant increases in the proportion and concentration of plasma high molecular weight fibrin(ogen) complexes (HMWFC). An inverse correlation (p<0.05) between coagulation factor XIII concentration and percentage of HMWFC was demonstrated in the early stages of the illness. These findings suggest that depression of coagulation factor XIII concentration in these states, is secondary to extra vascular or intravascular coagulation and may reflect its degree.

Full Text

References

References
1 Alkjaersig N, Roy L, Fletcher A, Murphy E. 1973; Analysis of gel exclusion chromatographic data by chromatographic plate theory analysis: Application to plasma fibrinogen chromatography. Thrombosis Research 3: 525.
2 Alkjaersig N, Fletcher A, Burnstein R. 1975; Association between oral contraceptive use and thromboembolism: A new approach to its investigation based on plasma fibrinogen chromatography. American Journal of Obstetrics and Gynaecology 122: 199.
3 Alkjaersig N, Fletcher A, Lewis M, Cole B, Ingelfinger J, Robson A. 1976; Pathophysiological response of blood coagulation system in acute glomerulonephritis. Kidney International 10: 319.
4 Armitage P. 1971. Statistical methods in medical research. John Wiley and Sons; New York.:
5 Cooper H, Bowie E, Didisheim P, Owen Jr. C. 1971; Paradoxic changes in platelets and fibrinogen in chronically-induced intravascular coagulation. Mayo Clinic Proceedings 46: 521.
6 Coopland A, Alkjaersig N, Fletcher A. 1969; Reduction in plasma factor XIII (fibrin stabilizing factor) concentration during pregnancy. Journal of Laboratory and Clinical Medicine 73: 144.
7 Cooperative Clinical Trial.. 1973; Anticoagulants in acute myocardial infarction. Journal of the American Medical Association 225: 724.
8 Duckert F, Jung E, Schmerling D. 1960; A hitherto undescribed congenital hemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thrombosis et Diathesis Haemorrhagica 5: 179.
9 Fletcher A, Alkjaersig N, O’Brien J, Tulevski V. 1970; Blood hypercoagulability and thrombosis. Transactions of the Association of American Physicians 83: 159.
10 Fletcher A, Alkjaersig N, Roy L, Owens O. 1972. a Early detection of blood hypercoagulable states and early thromboembolic lesions in man. In: Erdrich M. (ed.) Advances in automated analysis. 1972. Technicon International Congress. Mediaid, Incorporated; Tarrytown: vol. 4 31.
11 Fletcher A, Alkjaersig N. 1972; b Blood hypercoagulability, intravascular coagulation and thrombosis: New diagnostic concepts. Thrombosis et Diathesis Haemorrhagica Suppl. 45: 389.
12 Fletcher A, Alkjaersig N, Ghani M, Tulevski V. 1973; a Response of blood coagulation and plasma fibrinolytic enzyme systems in acute myocardial infarction. Clinical Research 21: 862.
13 Fletcher A, Alkjaersig N, Davies A, Lewis M, Brooks J, Hardin W, Landau W, Raichle M. 1976; Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke. Stroke 7: 337.
14 Fletcher A, Alkjaersig N, O’Brien J, Tulevski V. 1977; a Fibrinogen catabolism in the surgically-treated patients and in those with post-operative venous thrombosis. Correlation of plasma fibrinogen chromatographic findings with ¹²⁵I-labelled fibrinogen scan findings. Journal of Laboratory and Clinical Medicine 89: 1349.
15 Fletcher A, Alkjaersig N. 1977 b The use and monitoring of antithrombotic drug therapy: The need for a new approach. Thrombosis and Haemostasis. in press.
16 Fletcher A, Alkjaersig N. 1977. c Physiological and pathophysiological study of blood coagulation system function by plasma fibrinogen chromatography. In: Ritchie R. (ed.) Automated Immunoanalysis. Marcel Dekker; New York: in press.
17 Ittyerah R, Alkjaersig N, Fletcher A, Chaplin Jr. H. 1976; Coagulation factor XIII concentration in sickle cell disease. Journal of Laboratory and Clinical Medicine 88: 546.
18 Laki K. (ed.) 1972; The biological role of the clot stabilizing enzymes: Transglutaminase and factor XIII. Annals of the New York Academy of Science 202: 348.
19 Lewis J. 1972; Hemorrhagic disease associated with inhibitors of fibrin crosslinkage. In: The biological role of clot stabilizing enzymes: Transglutaminase and factor XIII. Annals of the New York Academy of Science 202: 213.
20 Lorand L, Dickenman R. 1955; Assay method for the “fibrin stabilizing factor”. Proceedings of the Society of Experimental Biology and Medicine 89: 45.
21 Lorand L, Jacobsen A, Bruner-Lorand J. 1968; A pathological inhibitor of fibrin cross-linking. Journal of Clinical Investigation 47: 268.
22 Lorand L, Urayama T, DeKiewiet J, Nossel H. 1969; Diagnostic and genetic studies in fibrin stabilizing factor with a new assay based on amine incorporation. Journal of Clinical Investigation 48: 1054.
23 Mancini G, Carbonara A, Heremans J. 1965; Immunochemical quantitation of antigens by single radial immunodiffusion. International Journal of Immunochemistry 2: 253.
24 McKay D. 1968; Pathology, diagnosis and therapy of disseminated intravascular coagulation. Proceedings of the Royal Society of Medicine 61: 1129.
25 Medical Research Council. 1969; Assessment of short-term anticoagulant administration after cardiac infarction. British Medical Journal 1: 335.
26 Merskey C, Johnson A, Kleiner G, Wohl H. 1967; The defibrination syndrome clinical features and laboratory diagnosis. British Journal of Hematology 13: 528.
27 Miloszewski K, Losowski M. 1970; The half-life of factor XIII in vivo. British Journal of Hematology 19: 685.
28 Nicolaides A, Kakkar V, Renney J, Kidner P, Hutchison D, Clarke M. 1971; Myocardial infarction and deep vein thrombosis. British Medical Journal 1: 432.
29 Nussbaum M, Morse B. 1964; Plasma fibrin stabilizing factor activity in various diseases. Blood 23: 669.
30 Owen Jr. C, Bowie E, Cooper H. 1973; Turnover of fibrinogen and platelets in dogs undergoing induced intravascular coagulation. Thrombosis Research 2: 251.
31 Rapaport S, Hjort P, Patch M, Jeremic M. 1966; Consumption of serum factors and prothrombin during intravascular clotting in rabbits. Scandinavian Journal of Hematology 3: 59.
32 Ratnoff O, Menzie C. 1951; A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 37: 316.
33 Warlow C, Ogston O, Douglas A. 1972; Venous thrombosis following strokes. Lancet I: 1305.
34 Welch D, Coleman R, Hardin W, Siegel B. 1975; Brain scanning in cerebrovascular disease. A reappraisal. Stroke 6: 136.